Evidence map›Paper›PMID 30518997›Full record

ArticleDrug design, development and therapy2018

The therapeutic effects of traditional Chinese medicine Fusu agent in LPS-induced acute lung injury model rats.

Peiyang Gao, Ziyi Zhao, Chuantao Zhang, Chunxia Wang, Kunlan Long, Liuxue Guo, Baixue Li

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. The preventative effects ofFrontiers in microbiology · 2024
    Article
  8. Article
  9. Article
  10. Protective Effects ofInternational journal of molecular sciences · 2022
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Protective effect ofBioscience reports · 2019
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Peiyang GaoIntensive Care Unit, The Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Ziyi ZhaoCentral Laboratory, The Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Chuantao ZhangIntensive Care Unit, The Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Chunxia WangIntensive Care Unit, The Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Kunlan LongIntensive Care Unit, The Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Liuxue GuoIntensive Care Unit, The Teaching Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Baixue LiCollege of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China, Baixuelee@163.com.
Chengdu University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeAcute lung injury (ALI) is a common and fatal oxidative stress in the lung, mainly induced by endothelial injury and capillary leakage. In our previous study, "Fusu agent", a traditional Chinese medicine, was found to exert preventive effect on endothelial damage in lipopoly-saccharide (LPS)-induced ALI model rats partially via inhibiting heparanase1 (HPA1) activation and inhibiting the inflammatory factors. However, it is still unknown whether Fusu agent exerts its therapeutic effect in LPS-induced ALI model rats and its potential mechanism. MATERIALS AND

methodsRats were injected with LPS (3 mg/kg, intraperitoneally) to induced ALI, and the prepared Fusu agent was given (2, 4 or 6 g/kg) 2 hours after LPS challenge. Twenty-four or 48 hours after Fusu agent administration, the biochemical changes in the plasma and lung tissues and the morphological/histological changes in the lung associated with inflammation and injury were evaluated. Human umbilical vein endothelial cells (HUVECs) were employed to confirm the therapeutic effects of Fusu agent and investigate its mechanisms, that is, affecting ROS accumulation, mitochondrial transmembrane potential (MTP) maintenance and decreasing the expression levels of HPA1.

resultsAdministration of Fusu agent obviously improved the lung injury and recovered vascular endothelium loss and injury. CD31 signal, which is a specific marker for endothelial vascular lesions, was decreased after Fusu agent treatment in LPS-induced ALI model rats, indicating its therapeutic effect against endothelial surface layer injury. Meanwhile, Fusu agent also decreased HPA1 expression and inflammatory responses. In vitro, Fusu agent-medicated serum decreased injury and cell death induced by LPS in HUVECs by stabilizing MTP and decreasing the leakage of lactate dehydrogenase. Consistently, Fusu agent-medicated serum downregulated HPA1 induced by LPS stimulation.

conclusionThese findings suggest that Fusu agent exerts its therapeutic effect in both LPS-induced ALI model rats and HUVECs potentially via suppressing HPA1 expression, and thus exerts prosurvival effect via maintaining MTP and attenuating cell injury.

Indexed as

Medicine, Chinese TraditionalAcute Lung InjuryAnimalsCell DeathCells, CulturedDisease Models, AnimalDrugs, Chinese HerbalHumansHuman Umbilical Vein Endothelial CellsInflammationKaplan-Meier EstimateLipopolysaccharidesMaleRatsRats, WistarReactive Oxygen SpeciesDrugs, Chinese HerbalLipopolysaccharidesReactive Oxygen Speciesacute lung injuryALIheparanaseHUVECsmitochondrial transmembrane potentialROS accumulation

Identifiers

PMID30518997
PMCPMC6239118
OpenAlexW2901345731

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.